edu磨課師+ 臨床藥學系列 生物製劑新藥與實例 影音教學 英文發音 英文版(DVD版)
【課程簡介】
開課學校/機構:臺北醫學大學
課程發展年度:2019
課程類別:醫學_醫藥衛生
邀請北醫客座師資，以全英文講授以學生為本體之理論與實際模式，以案例導向教育藥學新知中較難以掌握的藥理生物製劑新藥。
【學習目標】
使學員了解正確學習生物製劑之原理
使學員了解生物製劑之製劑步驟與藥物動力學評估
使學員理解目前上市生物製劑之種類和臨床研究
使學員了解生物製劑於臨床運用實例及相關議題討論
001_1.1-Course-Overview.mp4
002_1.2-Introduction-to-Biotechnology.mp4
003_1.3-Early-History-of-Biotechnology.mp4
004_1.4-Ground-Breaking-Discoveries-of-the-20th-Century.mp4
005_1.5-Recombinant-DNA-and-Hybridoma-Technology.mp4
006_1.6-A-Few-!§Firsts!‥.mp4
007_1.7-Polymerase-Chain-Reaction.mp4
008_1.8-A-Flurries-of-Discoveries-and-Accomplishments.mp4
009_1.9-RNA-Interference.mp4
010_1.10-Cloning-Technology.mp4
011_1.11-Unlimited-Biotechnology-Applications.mp4
012_1.12-Discoveries-and-Accomplishments-of-the-Early-21st-Century.mp4
013_1.13-Biologics-on-the-Rise.mp4
014_1.14-Pharmacist!|s-Opportunities-and-Challenges.mp4
015_2.1-Introduction-to-Biotechnology-Techniques-and-Tools.mp4
016_2.2-Hybridoma-Technology.mp4
017_2.3-Pegylation-and-Glycosylation.mp4
018_2.4-Polymerase-Chain-Reaction.mp4
019_2.5-Biogenetic-Engineering.mp4
020_2.6-Vector-Technology.mp4
021_2.7-Antisense-Technology.mp4
022_2.8-Cloning-of-Dolly-the-Sheep.mp4
023_2.9-Peptide-Technology.mp4
024_2.10-Bioinformatics.mp4
025_3.1-Immunity-and-Immunogenicity.mp4
026_3.2-The-Immune-System.mp4
027_3.3-Immunities-Overview.mp4
028_3.4-Immunogenic-Response.mp4
029_3.5-Chimerization-and-Humanization.mp4
030_3.6-Pegylation-and-Glycosylation.mp4
031_3.7-Formulation-Factors.mp4
032_3.8-Immunogenicity-Overview.mp4
033_4.1-Formulating-Biologics.mp4
034_4.2-Improving-Bioavailability.mp4
035_4.3-What-Happens-After-Biologics-are-Subcutaneously-Administrated-.mp4
036_4.4-Biologics-Elimination---How-Does-Structural-Modification-Change-it-.mp4
037_4.5-Targeted-Drug-Delivery.mp4
038_4.6-Excipients-(Additives)-in-Parenteral-Biologics.mp4
039_4.7-Additional-Excipients.mp4
040_4.8-Injectable-Biologics.mp4
041_4.9-Microbiological-Considerations-of-Biotechnology-Products.mp4
042_4.10-Quality-Control-of-Injectable-Biologics.mp4
043_5.1-Introduction-to-PK-PD-correlation.mp4
044_5.2-Differences-Between-Biologics-and-Small-Molecule-Drugs.mp4
045_5.3-Transport-of-Biologics-in-the-Body.mp4
046_5.4-Macromolecule-Binding.mp4
047_5.5-Pharamcokinetic-Characteristics-of-Biologics.mp4
048_5.6-Elimination-Pathways-of-Biologics.mp4
049_5.7-Receptor-Mediated-Metabolism.mp4
050_5.8-Immunogenicity-and-PK-PD.mp4
051_5.9-PK-PD-Modeling.mp4
052_5.10-Indirect-Link-PK-PD-Model.mp4
053_5.11-Indirect-Link-Model-and-Clockwise-Hysteresis.mp4
054_5.12-Indirect-Response-Model-and-Cell-Life-Span-Model.mp4
055_5.13-Complex-Response-Model.mp4
056_6.1-Product-Introduction.mp4
057_6.2-Biologics-and-Biosimilar-Overview.mp4
058_6.3-Anti-Hemophilic-Factors.mp4
059_6.4-Anti-coagulant.mp4
060_6.5-Antisense-Oligonucleotides-and-colony-Stimulating-Factors.mp4
061_6.6-Erythropoietin-and-Grow-Hormone.mp4
062_6.7-Interferons.mp4
063_6.8-Interleukins.mp4
064_6.9-Monoclonal-Antibodies.mp4
065_6.10-Reverse-Transcriptase-Inhibitors.mp4
066_6.11-Tissue-Necrosis-Factor-and-Tyrosine-Kinase-Inhibitor.mp4
067_6.12-Role,-Challenge-and-Opportunity.mp4
|
|
您現在的位置：
專業知識教學
